Voriconazole-induced QT prolongation among hemato-oncologic patients: clinical characteristics and risk factors

Voriconazole-induced QT prolongation among hemato-oncologic patients: clinical characteristics... Purpose The purpose of this study is to determine the rate of tients treated with voriconazole are at increased risk for QTcP, QTcP and associated risk factors in patients treated with especially in the presence of baseline QTc ≥ 450 msec and low voriconazole. serum potassium levels. Methods We conducted a retrospective chart review of all . . patients treated with voriconazole in a large tertiary center Keywords Voriconazole QT prolongation Adverse . . between 2009 and 2015, using paired comparison of QTc effects Torsadedepointes Safety intervals on and off voriconazole treatment, adjusted for co- morbidities, electrolyte abnormalities, and concurrent medications. Background Results Fifty-four patients were included, of whom 53 were diagnosed with oncologic/hemato-oncologic disease. Mean Voriconazoleisapotentantifungalagentmainlyusedinimmune- QTc during voriconazole therapy (448.0 ± 52.9 msec) was compromised hemato-oncologic patients suffering from inva- significantly longer compared to QTc off voriconazole sive aspergillosis or candida infections [1]. Among the various (421.8 ± 42.2 msec; p = 0.002). QTcP ≥30 msec and ≥60 msec adverse events that have been associated with voriconazole, was demonstrated in 43% (23 patients) and 28% (15 patients), corrected QT interval prolongation (QTcP) is the most respectively. Multivariate analysis showed that QTcP was sig- concerning given its propensity http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Clinical Pharmacology Springer Journals

Voriconazole-induced QT prolongation among hemato-oncologic patients: clinical characteristics and risk factors

Loading next page...
 
/lp/springer_journal/voriconazole-induced-qt-prolongation-among-hemato-oncologic-patients-F0JH7Ek0m0
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2017 by Springer-Verlag GmbH Germany
Subject
Biomedicine; Pharmacology/Toxicology
ISSN
0031-6970
eISSN
1432-1041
D.O.I.
10.1007/s00228-017-2284-5
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial